Ultima-Tirzepatide, 5 mg

Ultima-Tirzepatide 5 mg contains tirzepatide, a dual GIP and GLP-1 receptor agonist associated with appetite regulation, blood-glucose control, weight management, and metabolic support. Its dual mechanism makes it particularly relevant to weight-loss and body-composition-focused applications.

How it works

Tirzepatide activates both GIP and GLP-1 receptors, two pathways involved in appetite, glucose regulation, insulin activity, and energy balance.

This combined activity promotes satiety and appetite control, supports glucose-dependent insulin secretion, reduces glucagon activity, and slows gastric emptying. Together, these effects can help reduce calorie intake and support progressive changes in body weight.

Proper Use and Dosage

The listed presentation contains 5 mg of tirzepatide.

The standard labeled dosing schedule starts at 2.5 mg once weekly for 4 weeks, followed by 5 mg once weekly. If additional response is needed, the dose may be increased in 2.5 mg increments after at least 4 weeks at the current dose. Recommended maintenance doses include 5 mg, 10 mg, or 15 mg once weekly, with 15 mg once weekly as the maximum recommended dosage.

For a 5 mg presentation:

• 2.5 mg = 2 administrations
• 5 mg = 1 full presentation
• 7.5 mg = 1.5 presentations
• 10 mg = 2 presentations
• 12.5 mg = 2.5 presentations
• 15 mg = 3 presentations

For weight-management applications, tirzepatide is generally administered once weekly, with gradual dose escalation to improve tolerability.

Benefits

Ultima-Tirzepatide is particularly suited to applications involving weight management, appetite control, metabolic health, and body composition.

Key benefits and areas of interest include:

• Supports appetite control
• Promotes increased feelings of fullness
• Supports weight-loss goals
• Helps regulate blood-glucose levels
• Supports insulin sensitivity
• Supports glucose-dependent insulin activity
• Slows gastric emptying
• Supports improved metabolic function
• May complement calorie-controlled nutrition programs
• Supports long-term body-composition management
• Convenient 5 mg presentation

Its dual GIP and GLP-1 receptor activity gives tirzepatide a distinctive approach to combining appetite regulation with metabolic support.

Side Effects

Possible effects may include nausea, diarrhea, constipation, vomiting, abdominal discomfort, indigestion, decreased appetite, and injection-site reactions. Some individuals may also experience fatigue, belching, or temporary gastrointestinal discomfort, particularly during dose increases.